Laurus Labs Ltd share price logo

Laurus Labs Ltd (LAURUSLABS)


Get free price alerts. Set up your Free investment account to get Live Prices.
Q3 '23 Results
News and Events

Insights on Laurus Labs Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    Revenue Rich


    Revenue is up for the last 2 quarters, 1.19K Cr → 1.45K Cr (in ₹), with an average increase of 17.9% per quarter


    Profit Spike


    Netprofit is up for the last 2 quarters, 23.14 Cr → 75.61 Cr (in ₹), with an average increase of 69.4% per quarter


    MF Holding Up


    Mutual Funds have increased holdings from 5.58% to 6.68% in Mar 2024 quarter


    FII Holding Up


    Foreign Institutions have increased holdings from 25.39% to 25.97% in Mar 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged


    Promoters holdings remained unchanged at 27.19% of holdings in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers


    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 120.7% return, outperforming this stock by 152.0%

  • imgNO EFFECT

    Against Peers


    In the last 1 year, Zydus Lifesciences Ltd has given 93.1% return, outperforming this stock by 74.3%


    Retail Holding Down


    Retail Investor have decreased holdings from 36.29% to 35.07% in Mar 2024 quarter


    Price Dip


    In the last 3 years, LAURUSLABS stock has moved down by -31.3%


  • Day's Low

    Day's High

  • 52 Week's Low

    52 Week's High

1 Month Return-1.96 %
3 Month Return+ 8.14 %
1 Year Return+ 18.8 %
Previous Close₹430.00
Upper Circuit-
Lower Circuit-
Market Cap₹23,175.53Cr

Analyst Rating

based on 14 analysts


Based on 14 analysts offering long term price targets for Laurus Labs Ltd. An average target of ₹385.07

Source: S&P Global Market Intelligence

Company Information

Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in the production of generic active pharmaceutical ingredients (APIs) in high-growth therapeutic areas like antiretrovirals (ARVs), Hepatitis C, and Oncology. The company operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh, and has invested significantly in their RD and manufacturing infrastructure, having launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma, Strides Shasun, among others. It has 34 owned patents plus 152 pending patent applications in various countries. It is increasingly focused on their integrated generics finished dosage forms FDFs business, having acquired of Sriam Labs and Richcore Lifesciences in the recent years. During 2020, it launched Hydroxychloroquine, initiated TLD supplies for the Global Fund tender, and bargained partnerships with various private and public organizations. On 2022, it infused capital in Laurus Generics Inc . and infused around Rs 46 crore to acquire a stake in Immunoadoptive Cell Therapy Private Limited, among other expansions and operations.

Share Price: ₹429.75 per share as on 24 Jun, 2024 11:44 AM
Market Capitalisation: ₹23,175.53Cr as of today
Revenue: ₹1,439.67Cr as on March 2024 (Q1 24)
Net Profit: ₹75.32Cr as on March 2024 (Q1 24)
Listing date: 19 Dec, 2016
Chairperson Name: M V G Rao
OrganisationLaurus Labs Ltd
E-voting on sharesClick here to vote

Key events for Laurus Labs Ltd

  • CARE Ratings Revises Outlook on Laurus Labs' Long-Term Credit Facilities to Negative - 18 Jun, 2024

    CARE Ratings has revised its outlook on the long-term credit facilities of Laurus Labs to negative from stable, while affirming the rating at CARE AA. The company's Q4 FY24 net profit dropped 26.58% YoY to Rs 75.61 crore, while revenue from operations increased 4.26% YoY to Rs 1,439.67 crore.

  • Laurus Labs Stock Gains Over Last Year - 11 Jun, 2024

    Laurus Labs stock gains 29.35% in last one year, outpacing NIFTY but lagging behind Nifty Pharma. The company's EPS growth was slower than its share price growth over five years.

  • Laurus Labs Ltd Up 2.73% on NSE - 07 Jun, 2024

    Laurus Labs Ltd is up 2.73% on the NSE, trading at Rs 440.6 as of 12:49 IST. The stock has gained 26.92% in the last year compared to a 24.64% increase in the NIFTY and a 51.19% rise in the Nifty Pharma index.

  • Laurus Labs CEO Confident in CDMO Business Growth - 28 May, 2024

    Satyanarayana Chava, Founder and CEO of Laurus Labs, is optimistic about the growth potential of their contract development and manufacturing organisation (CDMO) business this year. The company already supplies four APIs for new chemical entities (NCEs), with two abbreviated new drug applications (ANDAs) being filed using their API in the US. They hope to achieve 20% plus EBITDA margins this year and will not increase debt beyond INR 2,500 crore.

  • USFDA Sends Untitled Letter to Laurus Labs' Andhra Unit - 24 May, 2024

    Laurus Labs received an untitled letter from the USFDA regarding deviations from current good manufacturing practices (cGMP) for active pharmaceutical ingredients (APIs) at its Andhra Pradesh facility. The USFDA has recommended that Laurus engage a consultant to help meet cGMP requirements.

  • Laurus Labs Ltd Up 1.2% on NSE - 22 May, 2024

    Laurus Labs Ltd is trading at Rs 458.85, up 1.2% on the day and has gained 45.92% in the last year compared to a 23% jump in NIFTY and a 56.21% jump in the Nifty Pharma index. The stock's PE ratio based on TTM earnings ending March 24 is 109.25.

  • Institutional Owners Hold 34% Shares in Laurus Labs - 21 May, 2024

    Nsn Holdings is the largest shareholder of Laurus Labs with 23% shares, followed by Capital Research and Management Company owning 11%. Insider ownership is positive. The general public owns 34%, while private companies own 28%.

Laurus Labs Ltd Valuation

Laurus Labs Ltd in the last 5 years

  • Overview

  • Trends

Lowest (16.96x)

March 28, 2023

Industry (64.94x)

June 21, 2024

Today (144.30x)

June 21, 2024

Highest (193.71x)

September 18, 2020


Mutual Fund Holdings

Funds Holdings
Mirae Asset Large & Midcap Fund Direct Plan GrowthMirae Asset Large & Midcap Fund Direct Plan Growth1.23%
Mirae Asset ELSS Tax Saver Fund -Direct Plan-GrowthMirae Asset ELSS Tax Saver Fund -Direct Plan-Growth1.7%
Mirae Asset Midcap Fund Direct GrowthMirae Asset Midcap Fund Direct Growth1.41%
PGIM India Midcap Opportunities Fund Direct GrowthPGIM India Midcap Opportunities Fund Direct Growth1.05%
SBI Magnum Midcap Fund Direct GrowthSBI Magnum Midcap Fund Direct Growth0.56%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Laurus Labs Ltd shares.

Laurus Labs Ltd (LAURUSLABS) share price today is ₹429.75

Laurus Labs Ltd is listed on NSE

Laurus Labs Ltd is listed on BSE

  • Today’s highest price of Laurus Labs Ltd is ₹429.85.
  • Today’s lowest price of Laurus Labs Ltd is ₹429.35.

PE Ratio of Laurus Labs Ltd is 144.3

PE ratio = Laurus Labs Ltd Market price per share / Laurus Labs Ltd Earnings per share

Today’s traded volume of Laurus Labs Ltd(LAURUSLABS) is 10.84L.

Today’s market capitalisation of Laurus Labs Ltd(LAURUSLABS) is ₹23175.53Cr.

Laurus Labs Ltd(LAURUSLABSPrice
52 Week High
52 Week Low

Laurus Labs Ltd(LAURUSLABS) share price is ₹429.75. It is down -8.76% from its 52 Week High price of ₹471

Laurus Labs Ltd(LAURUSLABS) share price is ₹429.75. It is up 30.96% from its 52 Week Low price of ₹328.15

Laurus Labs Ltd(LAURUSLABSReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns